Reply to thread

Rockin the Morphosys to a huge 90 million a year WOW. pela a BET inhibitor used in combination with JAKAFI, Incyte is doing their own trial  with their own BET inhibitor ????????? plus pancritinib monotherapy causes no cytopenias and can be used with platelets less than 50k. Why use two drugs when one works wonderfully. Also the way Constiellaton was (bought) the stock went from 27 to 5 bucks. great investment in a 15,000 US pateints with over 10 new compounds that are better than pela bring appropved this year. Just google "should i buy MOR stock?"